First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in Caucasian patients (pts) (NCT00339586)-FIELT study group.


7597 Background: Compared to chemotherapy, 1st line treatment with EGFR-TK inhibitors results in superior progression-free survival (PFS) in Asian patients with advanced NSCLC with activating EGFR TK domain mutations. We conducted a prospective study with 1st line erlotinib in Caucasian pts with EGFR TK domain mutations. METHODS Multicentre phase II study… (More)